These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 1664137)

  • 21. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell therapy for cytomegalovirus infection.
    Mui TS; Kapp M; Einsele H; Grigoleit GU
    Curr Opin Organ Transplant; 2010 Dec; 15(6):744-50. PubMed ID: 20930639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.
    Paine A; Oelke M; Tischer S; Heuft HG; Blasczyk R; Eiz-Vesper B
    J Immunother; 2010 Jan; 33(1):60-72. PubMed ID: 19952955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.
    Horn B; Bao L; Dunham K; Stamer M; Adler S; Cowan M; Lucas K
    Pediatr Infect Dis J; 2009 Jan; 28(1):65-7. PubMed ID: 19034064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CMV-specific T cell therapy.
    Einsele H; Kapp M; Grigoleit GU
    Blood Cells Mol Dis; 2008; 40(1):71-5. PubMed ID: 17851094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive T cell immunotherapy for cytomegalovirus.
    Peggs KS
    Expert Opin Biol Ther; 2009 Jun; 9(6):725-36. PubMed ID: 19456207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions.
    Peggs K; Verfuerth S; Mackinnon S
    Blood; 2001 Feb; 97(4):994-1000. PubMed ID: 11159528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
    Lemmermann NA; Reddehase MJ
    Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.
    Bao L; Cowan MJ; Dunham K; Horn B; McGuirk J; Gilman A; Lucas KG
    J Immunother; 2012 Apr; 35(3):293-8. PubMed ID: 22421947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adoptive transfer of cytomegalovirus-specific effector CD4+ T cells provides antiviral protection from murine CMV infection.
    Jeitziner SM; Walton SM; Torti N; Oxenius A
    Eur J Immunol; 2013 Nov; 43(11):2886-95. PubMed ID: 23921569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.
    Pfirrmann V; Oelsner S; Rettinger E; Huenecke S; Bonig H; Merker M; Wels WS; Cinatl J; Schubert R; Klingebiel T; Bader P
    Cytotherapy; 2015 Aug; 17(8):1139-51. PubMed ID: 26072027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
    Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
    Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy.
    Vaz-Santiago J; Lulé J; Rohrlich P; Kravtzoff R; Le Roy E; Davignon JL; Betbeder D; Davrinche C
    Cytotherapy; 2002; 4(1):11-9. PubMed ID: 11953037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation].
    Xu Z; Huang X; Sun Y; Wang F; Yan C; Zhang X; Han W; Chen Y; Wang J; Chen H; Wang Y; Zhang Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):101-5. PubMed ID: 25907838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene transfer for activation of CMV specific T cells.
    André-Schmutz I; Dal Cortivo L; Hamel Y; Cavazzana-Calvo M
    Hum Immunol; 2004 May; 65(5):565-70. PubMed ID: 15172458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants.
    Lacey SF; Gallez-Hawkins G; Crooks M; Martinez J; Senitzer D; Forman SJ; Spielberger R; Zaia JA; Diamond DJ
    Transplantation; 2002 Sep; 74(5):722-32. PubMed ID: 12352893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immune reaction to human cytomegalovirus].
    Ito M
    Nihon Rinsho; 1998 Jan; 56(1):62-8. PubMed ID: 9465666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impairment of cytomegalovirus-specific cellular immune response as a risk factor for cytomegalovirus disease in transplant recipients.
    Motta VN; Martins SL
    Braz J Med Biol Res; 2008 Jan; 41(1):5-11. PubMed ID: 18060322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.